ArticleCurrent protocols in stem cell biology2015
Crispr-mediated Gene Targeting of Human Induced Pluripotent Stem Cells.
Article in Current protocols in stem cell biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- CRISPR-associated transposon for programmable viral vector engineering and prime editing.Nucleic acids research · 2026Article
- Stem cell modeling of nervous system tumors.Disease models & mechanisms · 2024Review
- Article
- Microfluidic processing of stem cells for autologous cell replacement.Stem cells translational medicine · 2021Review
- Cortical overgrowth in a preclinical forebrain organoid model of CNTNAP2-associated autism spectrum disorder.Nature communications · 2021Article
- Modeling Human TBX5 Haploinsufficiency Predicts Regulatory Networks for Congenital Heart Disease.Developmental cell · 2021Article
- HK022 bacteriophage Integrase mediated RMCE as a potential tool for human gene therapy.Nucleic acids research · 2020Article
- Enabling large-scale genome editing at repetitive elements by reducing DNA nicking.Nucleic acids research · 2020Article
- Modeling Psychiatric Disorder Biology with Stem Cells.Current psychiatry reports · 2020Review
- Article
- Generation of Knockout Gene-Edited Human Intestinal Organoids.Methods in molecular biology (Clifton, N.J.) · 2020Article
- Developing precision medicine using scarless genome editing of human pluripotent stem cells.Drug discovery today. Technologies · 2018Review
- CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration.Progress in retinal and eye research · 2018Review
- CRISPR-Cas9-Based Genome Editing of Human Induced Pluripotent Stem Cells.Current protocols in stem cell biology · 2018Article
- Scarless Genome Editing of Human Pluripotent Stem Cells via Transient Puromycin Selection.Stem cell reports · 2018Article
- Induced Pluripotent Stem Cells Meet Genome Editing.Cell stem cell · 2016Review
- Gene delivery methods and genome editing of human pluripotent stem cells.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation OncologyReview
- Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening.Biotechnology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
CRISPR/Cas9 nuclease systems can create double-stranded DNA breaks at specific sequences to efficiently and precisely disrupt, excise, mutate, insert, or replace genes. However, human embryonic stem or induced pluripotent stem cells (iPSCs) are more difficult to transfect and less resilient to DNA damage than immortalized tumor cell lines. Here, we describe an optimized protocol for genome engineering of human iPSCs using a simple transient transfection of plasmids and/or single-stranded oligonucleotides. With this protocol, we achieve transfection efficiencies greater than 60%, with gene disruption efficiencies from 1-25% and gene insertion/replacement efficiencies from 0.5-10% without any further selection or enrichment steps. We also describe how to design and assess optimal sgRNA target sites and donor targeting vectors; cloning individual iPSC by single cell FACS sorting, and genotyping successfully edited cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.